 |
|  Oregon Health and Science University |
|
| Oregon Health and Science University |
We are studying cellular signaling pathways involved in the generation of human cancer. In general, disruption of these pathways alters the ability of a cell to control its proliferation as well as the initiation of programmed cell death (apoptosis). We are focusing on three key signaling pathways that regulate both cellular proliferation and apoptosis: the Myc transcription factor, the Ras signaling protein, and the G1 cyclin dependent kinase (Cdk)/retinoblastoma(Rb)/E2F pathway. While each of these pathways has been extensively studied over the past decade, the nature of their interrelations remains elusive. Since these pathways are deregulated in the majority of all human tumors, we want to understand how they network and synergize to precisely control cellular proliferation versus cell death. This information will contribute to our understanding of the complex nature of cancer progression, and facilitate the generation of meaningful therapies.
Member:
Taylor, Karyn
Role:
Lab Manager, Research Assistant 2
Lck-cre transgenic mice contain a Cre-recombinase gene driven by the distal promoter of the lymphocyte protein tyrosine kinase (Lck) gene.
BLG-Cre transgenic mice have the beta-lactoglobulin (BLG) promoter directing Cre recombinase expression to mammary gland during lactation.
An immunoglobin enhancer inducing expression of the rtTA which then proceeds to subsequent doxycycline "inducibility".
Cre recombinase progesterone receptor (PR) fusion protein under control of Keratin 5 promoter.
Lck-cre transgenic mice contain a Cre-recombinase gene driven by the distal promoter of the lymphocyte protein tyrosine kinase (Lck) gene.
LSL-KrasG12D carry a latent point-mutant allele of Kras2 (K-rasG12D). Cre-mediated recombination leads to deletion of a transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic protein.
LSL-KrasG12D carry a latent point-mutant allele of Kras2 (K-rasG12D). Cre-mediated recombination leads to deletion of a transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic protein.
P48-Cre is a pancreas-specific Cre recombinase transgene.
LSL-KrasG12D carry a latent point-mutant allele of Kras2 (K-rasG12D). Cre-mediated recombination leads to deletion of a transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic protein.
Pdx-1-Cre mice exhibit a stochastic pattern of high-level Cre expression in the pancreas .
Double homozygous for the severe combined immunodeficiency (SCID) mutation and interleukin-2Rgamma (IL-2Rgamma) allelic mutation (gamma(c)(null)).
Pancreas-specific Cre recombinase transgene.
Pdx-1-Cre mice exhibit a stochastic pattern of high-level Cre expression in the pancreas .
Lck-cre transgenic mice contain a Cre-recombinase gene driven by the distal promoter of the lymphocyte protein tyrosine kinase (Lck) gene.
Wap-cre mice express Cre in the secretory luminal and ductal epithelial cells of the mammary gland during late pregnancy and lactation.
Cre recombinase progesterone receptor (PR) fusion protein under control of Keratin 5 promoter.
Wap-cre mice express Cre in the secretory luminal and ductal epithelial cells of the mammary gland during late pregnancy and lactation.
Cre recombinase progesterone receptor (PR) fusion protein under control of Keratin 5 promoter.
LSL-KrasG12D carry a latent point-mutant allele of Kras2 (K-rasG12D). Cre-mediated recombination leads to deletion of a transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic protein.
LSL-KrasG12D carry a latent point-mutant allele of Kras2 (K-rasG12D). Cre-mediated recombination leads to deletion of a transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic protein.
P48-Cre is a pancreas-specific Cre recombinase transgene.
Pancreas-specific Cre recombinase transgene.
Pdx-1-Cre mice exhibit a stochastic pattern of high-level Cre expression in the pancreas .
LSL-KrasG12D carry a latent point-mutant allele of Kras2 (K-rasG12D). Cre-mediated recombination leads to deletion of a transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic protein.
LSL-KrasG12D carry a latent point-mutant allele of Kras2 (K-rasG12D). Cre-mediated recombination leads to deletion of a transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic protein.
Pdx-1-Cre mice exhibit a stochastic pattern of high-level Cre expression in the pancreas .
P48-Cre is a pancreas-specific Cre recombinase transgene.
Pdx-1-Cre mice exhibit a stochastic pattern of high-level Cre expression in the pancreas .
BLG-Cre transgenic mice have the beta-lactoglobulin (BLG) promoter directing Cre recombinase expression to mammary gland during lactation.
Cre recombinase progesterone receptor (PR) fusion protein under control of Keratin 5 promoter.
Lck-cre transgenic mice contain a Cre-recombinase gene driven by the distal promoter of the lymphocyte protein tyrosine kinase (Lck) gene.
LSL-KrasG12D carry a latent point-mutant allele of Kras2 (K-rasG12D). Cre-mediated recombination leads to deletion of a transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic protein.
Pdx-1-Cre mice exhibit a stochastic pattern of high-level Cre expression in the pancreas .
BLG-Cre transgenic mice have the beta-lactoglobulin (BLG) promoter directing Cre recombinase expression to mammary gland during lactation.
LSL-KrasG12D carry a latent point-mutant allele of Kras2 (K-rasG12D). Cre-mediated recombination leads to deletion of a transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic protein.
LSL-KrasG12D carry a latent point-mutant allele of Kras2 (K-rasG12D). Cre-mediated recombination leads to deletion of a transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic protein.
P48-Cre is a pancreas-specific Cre recombinase transgene.
P48-Cre is a pancreas-specific Cre recombinase transgene.
Pdx-1-Cre mice exhibit a stochastic pattern of high-level Cre expression in the pancreas.
LSL-KrasG12D carry a latent point-mutant allele of Kras2 (K-rasG12D). Cre-mediated recombination leads to deletion of a transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic protein.
LSL-KrasG12D carry a latent point-mutant allele of Kras2 (K-rasG12D). Cre-mediated recombination leads to deletion of a transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic protein.
Pdx-1-Cre mice exhibit a stochastic pattern of high-level Cre expression in the pancreas .
P48-Cre is a pancreas-specific Cre recombinase transgene.
Pdx-1-Cre mice exhibit a stochastic pattern of high-level Cre expression in the pancreas.
BLG-Cre transgenic mice have the beta-lactoglobulin (BLG) promoter directing Cre recombinase expression to mammary gland during lactation.
Cre recombinase progesterone receptor (PR) fusion protein under control of Keratin 5 promoter.
Cre recombinase progesterone receptor (PR) fusion protein under control of Keratin 5 promoter.
Lck-cre transgenic mice contain a Cre-recombinase gene driven by the distal promoter of the lymphocyte protein tyrosine kinase (Lck) gene.
LSL-KrasG12D carry a latent point-mutant allele of Kras2 (K-rasG12D). Cre-mediated recombination leads to deletion of a transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic protein.
Pdx-1-Cre mice exhibit a stochastic pattern of high-level Cre expression in the pancreas .
BLG-Cre transgenic mice have the beta-lactoglobulin (BLG) promoter directing Cre recombinase expression to mammary gland during lactation.
Wap-cre mice express Cre in the secretory luminal and ductal epithelial cells of the mammary gland during late pregnancy and lactation.
Wap-cre mice express Cre in the secretory luminal and ductal epithelial cells of the mammary gland during late pregnancy and lactation.
Wap-cre mice express Cre in the secretory luminal and ductal epithelial cells of the mammary gland during late pregnancy and lactation.
Wap-cre mice express Cre in the secretory luminal and ductal epithelial cells of the mammary gland during late pregnancy and lactation.
PP2A B56alpha subunit wild type strain.
Promoter: T7
Promotor: T7
Promoter: T7
Promoter: T7
Promoter: T3
Promoter: CMV
Promoter: CMV
Contains V5-6xHis tag.
Promoter: CMV
Contains V5-6xHis (3'Epitope) tag.
Promoter: CMV
Promoter: CMV
Promoter: CMV
Promoter: CMV
Promoter: T7
Contains GST tag.
Promoter: ADH
Promoter: EF-1alpha
Promoter: T7
Promoter: EF-1alpha
Promoter: EF-1alpha
Promoter: EF-1alpha
Promoter: EF-1alpha
Promoter: EF-1alpha
Promoter: EF-1alpha
Contains flag tag.
Promoter: H1/TO
Promoter: H1/TO
Promoter: H1/TO
Promoter: U6, hPGK
Promoter: CMV
Promoter: CMV
Promoter: CMV
Promoter: CMV-TET
Promoter: CMV-TET
Promoter: CMV-TET
Promoter: CMV-TET, alpha isoform
Promoter: CMV-TET
